Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALDOMET vs AMJEVITA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.
Adalimumab is a recombinant human Ig G1 monoclonal antibody that binds specifically to tumor necrosis factor-alpha (TNF-α) and blocks its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses that are induced or regulated by TNF-α, including expression of adhesion molecules, chemotaxis, and pro-inflammatory cytokine release.
Hypertension (first-line in pregnancy-induced hypertension),Off-label: treatment of hypertensive crises
Rheumatoid arthritis (moderate to severe active, alone or with methotrexate),Juvenile idiopathic arthritis (moderate to active polyarticular, age ≥2 years),Psoriatic arthritis (active, alone or with DMARDs),Ankylosing spondylitis (active),Crohn's disease (moderate to severe, age ≥6 years),Ulcerative colitis (moderate to severe, adults),Plaque psoriasis (moderate to severe chronic, adults),Hidradenitis suppurativa (moderate to severe, adults),Uveitis (non-infectious intermediate, posterior, and panuveitis, adults and children ≥2 years)
250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.
Subcutaneous injection: 40 mg every other week; for patients with Crohn disease, an initial dose of 160 mg (given as four 40 mg injections in one day or two 40 mg injections per day for two consecutive days) followed by 80 mg at week 2 and 40 mg every other week starting at week 4.
1.5–2 hours (terminal elimination half-life); clinical context: Renal impairment prolongs half-life (up to 4–6 hours in severe impairment), necessitating dose adjustment.
Terminal elimination half-life is approximately 14 days (range 10-20 days) in patients receiving 40 mg every other week. This long half-life supports biweekly dosing.
Primarily hepatic metabolism via conjugation and O-methylation; also undergoes decarboxylation and deamination. Active metabolites include alpha-methyldopamine and alpha-methylnorepinephrine.
Adalimumab is a monoclonal antibody; it is not metabolized by cytochrome P450 enzymes. Clearance occurs via catabolism to small peptides and amino acids.
Renal: ~70% as unchanged drug and metabolites (sulfate conjugate, O-methylated derivatives); fecal/biliary: ~20%; <5% removed by hemodialysis.
Adalimumab (AMJEVITA) is eliminated primarily via intracellular catabolism, with negligible renal or biliary excretion. No intact drug is excreted in urine. The Fe receptor-mediated recycling contributes to long half-life.
~10-20% bound to plasma proteins (primarily albumin).
Adalimumab is a monoclonal antibody; protein binding is negligible as it is not bound to serum proteins. However, it may bind to soluble TNF-alpha with high affinity.
0.2–0.4 L/kg; clinical meaning: Moderate distribution, indicating limited extravascular penetration.
Volume of distribution (Vd) is approximately 4.7-6.0 L (0.06-0.08 L/kg for a 70 kg adult). This small Vd reflects distribution primarily in the vascular and interstitial spaces, consistent with a large protein.
Oral: ~50% (range 25-60%) due to first-pass metabolism; IV: 100%.
Subcutaneous bioavailability: 64% (range 50-80%) after 40 mg SC injection. No intravenous formulation is approved; absolute bioavailability determined by comparison to IV administration.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: interval every 12-24 hours; GFR <10 m L/min: interval every 24-48 hours or 250 mg every 36-48 hours.
No dose adjustment required for any degree of renal impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce dose by 75%.
No dose adjustment required for any degree of hepatic impairment.
10 mg/kg/day orally in 2-4 divided doses, increased gradually; maximum 65 mg/kg/day or 3 g/day.
For pediatric patients weighing ≥40 kg: 40 mg subcutaneously every other week; for weight <40 kg: 20 mg subcutaneously every other week.
Initial dose 250 mg once or twice daily; increase slowly; monitor for hypotension, sedation, and bradycardia; avoid in patients with pre-existing bradycardia or heart block.
No specific dose adjustment recommended; use with caution due to higher risk of infections.
None
Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), invasive fungal infections, and other opportunistic pathogens. Patients should be tested for latent TB before and during therapy. Malignancies, including lymphoma, have been reported in children and adolescents treated with TNF blockers.
Hepatic toxicity (fatal hepatic necrosis reported); hemolytic anemia (positive Coombs test common, may indicate hemolysis); sedation/drowsiness (impair mental alertness); orthostatic hypotension; caution in renal impairment (dose adjustment required); may cause positive direct Coombs test, which interferes with crossmatching; possible rebound hypertension upon abrupt discontinuation.
Serious infections (bacterial, viral, fungal, including reactivation of HBV),Invasive fungal infections (e.g., histoplasmosis, coccidioidomycosis, candidiasis),Malignancies (lymphoma, leukemia, melanoma, Merkel cell carcinoma, other),Anaphylaxis and allergic reactions,Demyelinating disease (new onset or exacerbation of CNS demyelinating disorders),Hematologic reactions (pancytopenia, aplastic anemia),Congestive heart failure (new onset or worsening),Lupus-like syndrome (autoantibodies, rarely clinical disease),Hepatitis B reactivation,Use with abatacept or anakinra (increased risk of infection)
Active hepatic disease (acute hepatitis, cirrhosis); prior methyldopa-induced hepatic dysfunction; concurrent MAO inhibitor therapy; hypersensitivity to methyldopa; pheochromocytoma.
Known hypersensitivity to adalimumab or any component of the formulation,Active serious infection including sepsis
Avoid excessive sodium intake, as it can counteract the antihypertensive effect. No specific food interactions reported, but alcohol may potentiate hypotension and sedation. Iron supplements may reduce absorption of methyldopa; separate administration by at least 2 hours.
No specific food interactions. No dietary restrictions required.
First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for management of chronic hypertension in pregnancy is common, but consider potential for reduced placental perfusion if maternal blood pressure is excessively lowered.
Amjevita (adalimumab) is an Ig G1 monoclonal antibody that crosses the placenta during the third trimester, with highest fetal exposure in the third trimester. In the first and second trimesters, placental transfer is limited. Available data from the OTIS autoimmune diseases in pregnancy study and other cohort studies do not indicate a substantially increased risk of major birth defects or miscarriage with adalimumab exposure during pregnancy. However, there is a potential risk of immunosuppression in the neonate, including increased risk of infections, if the mother is exposed during the second and third trimesters. Infants should not be vaccinated with live vaccines for at least 5 months after maternal last dose.
Methyldopa is excreted into breast milk in small amounts (M/P ratio approximately 0.2-0.5). At typical maternal doses, infant exposure is likely subtherapeutic and considered compatible with breastfeeding. Monitor infant for potential hypotension or sedation.
Adalimumab is excreted in breast milk in low concentrations. The milk-to-plasma ratio is approximately 0.04. Limited data indicate that infants are exposed to less than 1% of the maternal dose, and no adverse effects have been reported in breastfed infants. Because adalimumab is a large protein, it undergoes proteolysis in the infant's gastrointestinal tract and is not systemically absorbed. Therefore, breastfeeding is considered compatible with adalimumab therapy.
Pregnancy may increase volume of distribution and renal clearance, potentially reducing methyldopa plasma concentrations. Dose adjustments may be necessary to maintain blood pressure control; monitor and titrate based on maternal blood pressure response. Typical starting dose: 250 mg orally twice daily; maximum up to 3 g/day in divided doses, but lower doses are often effective.
During pregnancy, adalimumab clearance may increase, especially in the third trimester, leading to lower trough concentrations. However, no dose adjustment is routinely recommended due to lack of data showing altered clinical outcomes. Therapeutic drug monitoring is not standard, but if disease activity increases, consider modifying the dose or frequency as per non-pregnant guidelines. Postpartum, clearance returns to prepregnancy levels, so doses should be adjusted back to prepregnancy regimen if modified.
ALDOMET (methyldopa) is a centrally acting alpha-2 agonist used primarily for hypertension in pregnancy. Monitor for positive direct Coombs test, which can occur in up to 20% of patients on long-term therapy; this may interfere with cross-matching but rarely causes hemolysis. Hepatic adverse effects, including increased liver enzymes and rarely hepatitis, require monitoring. Sedation and dizziness are common initially; titrate dose slowly. Methyldopa may cause orthostatic hypotension; advise patients to rise slowly. A paradoxical pressor response may occur if given with MAO inhibitors.
AMJEVITA (adalimumab-atto) is a biosimilar to Humira. Administer subcutaneously; rotate injection sites. Do not administer live vaccines. Screen for TB and hepatitis B before initiation. Consider withholding for serious infections. Monitor for allergic reactions and blood dyscrasias.
Take exactly as prescribed; do not skip doses or stop suddenly as this may cause rebound hypertension.,This medication may cause drowsiness, especially at start of therapy; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying positions to minimize dizziness or fainting.,Report any unexplained fever, fatigue, jaundice (yellowing of skin/eyes), or dark urine to your healthcare provider immediately, as these may indicate liver problems.,Notify your doctor if you experience persistent dry mouth, flu-like symptoms, or swelling in the legs.,Regular blood pressure monitoring is essential; keep a log of readings.,Avoid alcohol, as it can increase drowsiness and lower blood pressure further.,Inform all healthcare providers, including dentists, that you are taking this medication.,Do not take any other medications, including over-the-counter products, without consulting your doctor.
Store in refrigerator, do not freeze; protect from light.,Inject at room temperature; allow to sit out 15-30 minutes.,Rotate injection sites; avoid tender, bruised, or scarred skin.,Report signs of infection (fever, chills, cough) or allergic reaction immediately.,Do not receive live vaccines while on this medication.,Inform all healthcare providers of your use of AMJEVITA.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALDOMET vs AMJEVITA, answered by our medical review team.
ALDOMET is a Central Alpha Agonist Antihypertensive that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.. AMJEVITA is a TNF-alpha Inhibitor that works by Adalimumab is a recombinant human Ig G1 monoclonal antibody that binds specifically to tumor necrosis factor-alpha (TNF-α) and blocks its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses that are induced or regulated by TNF-α, including expression of adhesion molecules, chemotaxis, and pro-inflammatory cytokine release.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALDOMET and AMJEVITA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALDOMET is: 250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.. The standard adult dose of AMJEVITA is: Subcutaneous injection: 40 mg every other week; for patients with Crohn disease, an initial dose of 160 mg (given as four 40 mg injections in one day or two 40 mg injections per day for two consecutive days) followed by 80 mg at week 2 and 40 mg every other week starting at week 4.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALDOMET and AMJEVITA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALDOMET is classified as Category C. First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for . AMJEVITA is classified as Category C. Amjevita (adalimumab) is an IgG1 monoclonal antibody that crosses the placenta during the third trimester, with highest fetal exposure in the third trimester. In the first and seco. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.